Citations

Clear

273 citation(s) found for "Simone, N De".

The genetic architecture of the human cerebral cortex
Grasby, Katrina L. , Jahanshad, Neda , Painter, Jodie N. , Colodro‐Conde, Lucía , Bralten, Janita , Hibar, Derrek P. , Lind, Penelope A. , Pizzagalli, Fabrizio , Ching, Christopher R. K. , McMahon, Mary , Shatokhina, Natalia , Zsembik, Leo , Thomopoulos, Sophia I. , Zhu, Alyssa H. , Strike, Lachlan T. , Alhusaini, Saud , Almeida, Marcio , Amlien, Inge K. , Andersson, Micael , Ard, Tyler , Armstrong, Nicola J. , Bernard, Manon , Brouwer, Rachel M. , Buimer, Elizabeth E.L. , Bürger, Christian, Cannon, Dara M. , Chen, Qiang , Cheung, J. , Couvy‐Duchesne, Baptiste , Dale, Anders M. , Dalvie, Shareefa , Araujo, Tânia Kawasaki de , Zubicaray, Greig I. de , Zwarte, Sonja M. C. de , Braber, Anouk den , Doan, Nhat Trung , Dohm, Katharina , Ehrlich, Stefan , Engelbrecht, Hannah-Ruth , Erk, Susanne , Fan, Chun Chieh , Fedko, Iryna O. , Foley, Sonya , Fukunaga, Masaki , Ge, Tian , Giddaluru, Sudheer, Goldman, Aaron L. , Green, Melissa J. , Groenewold, Nynke A. , Grotegerd, Dominik , Gurholt, Tiril P. , Hansell, Narelle K. , Harris, Mathew A., Harrison, Marc , Haswell, Courtney C. , Hauser, Michael A. , Heslenfeld, Dirk J., Ho, New Fei , Hoehn, David , Holleran, Laurena , Hottenga, Jouke‐Jan , Jansen, Iris E. , Jockwitz, Christiane , Karama, Sherif , Kasperavičiūtė, Dalia , Kaufmann, Tobias , Kelly, Sinéad, Kikuchi, Masataka , Klein, Marieke , Knapp, Michael , Knodt, Annchen R. , Krämer, Bernd , Lancaster, T. , Lewis, Lindsay B. , Mathias, Samuel R. , Melzer, Tracy R. , Milaneschi, Yuri , Mirza‐Schreiber, Nazanin , Moreira, José C.V. , Mühleisen, Thomas W. , Müller‐Myhsok, Bertram , Najt, Pablo , Nakahara, Soichiro , Orfanos, Dimitri Papadopoulos , Pitcher, Toni L. , Quidé, Yann , Ragothaman, Anjanibhargavi , Reay, William R. , Redlich, Ronny , Repple, Jonathan , Riedel, Brandalyn C. , Risacher, Shannon L. , Rocha, Cristiane S. , Salminen, Lauren E. , Saremi, Arvin , Schlag, Fenja, Schmaal, Lianne , Secolin, Rodrigo , Shapland, Chin Yang , Shumskaya, Elena , Sønderby, Ida E. , Sprooten, Emma , Tansey, Katherine E. , Teumer, Alexander , Thalamuthu, Anbupalam , Tordesillas‐Gutiérrez, Diana , Turner, Jessica A. , Uhlmann, Anne , Meer, Dennis van der , Donkelaar, Marjolein M. J. van , Eijk, Liza van , Haren, Neeltje E.M. van , Tol, Marie‐José van , Walton, Esther , Wang, Mingyuan, Wardlaw, Joanna M. , Wen, Wei , Whelan, Christopher D. , Wittfeld, Katharina , Wolf, Christiane , Wolfers, Thomas , Wu, Jing , Yasuda, Clarissa Lin , Zaremba, Dario , Zhang, Zuo , Zwiers, Marcel P. , Artiges, Éric , Assareh, Amelia A., Ayesa‐Arriola, Rosa , Belger, Ayşenil , Brandt, Christine L., Brown, Gregory G. , Cichon, Sven , Curran, Joanne E. , Davies, Gareth E., Degenhardt, Franziska , Dennis, Michelle F. , Dietsche, Bruno, Doherty, Colin P. , Espiritu, Ryan, Gowland, Penny , Häusler, Alexander N. , Heindel, Walter , Ho, Beng‐Choon , Holsboer, Florian , Hosten, Norbert , Jang, MiHyun , Jansen, Andreas , Koops, Sanne, Krug, Axel , Lim, Kelvin O. , Luykx, Jurjen J. , Mather, Karen A. , Mattay, Venkata S. , Son, Jacqueline Mayoral-van , McEwen, Sarah , Melle, Ingrid , Morris, Derek W. , Nöthen, Markus M. , OʼLeary, Daniel S. , Martinot, Marie‐Laure Paillère , Preda, Adrian , Quinlan, Erin Burke , Rasser, Paul E. , Reppermund, Simone , Steen, Vidar M. , Tooney, Paul A. , Torres, Fábio R. , Veltman, Dick J. , Voyvodic, James , White, Tonya , Yamamori, Hidenaga , Adams, Hieab H.H. , Bis, Joshua C. , Debette, Stéphanie , DeCarli, Charles , Fornage, Myriam , Guðnason, Vilmundur , Hofer, Edith , Ikram, M. Arfan , Longstreth, W.T. , Roshchupkin, Gennady V. , Satizábal, Claudia L. , Schmidt, Reinhold, Initiative¶, Alzheimer’s Disease Neuroimaging, Initiative¶, Parkinson’s Progression Markers, Alvim, Marina K. M. , Ames, David, Anderson, Tim , Blangero, John , Brodaty, Henry , Brunner, Han G. , Buckner, Randy L. , Buitelaar, Jan K. , Cairns, Murray J. , Calhoun, Vince D. , Caseras, Xavier , Caspers, Svenja , Cavalleri, Gianpiero L. , Cendes, Fernando , Corvin, Aiden , Crespo‐Facorro, Benedicto , Dalrymple‐Alford, John C. , Geus, Eco J. C. de , Deary, Ian J. , Delanty, Norman, Depondt, Chantal, Desrivières, Sylvane , Donohoe, Gary , Fisher, Simon E. , Flor, Herta , Forstner, Andreas J. , Francks, Clyde , Franke, Barbara , Glahn, David C., Gruber, Oliver , Hariri, Ahmad R. , Hartman, Catharina A. , Hashimoto, Ryota , Heinz, Andreas , Hillegers, Manon H. J. , Hoekstra, Pieter J. , Hong, L. Elliot , Pol, Hilleke E. Hulshoff , Jönsson, Erik G. , Kahn, René S. , Kennedy, Martin A. , Kircher, Tilo , Hellard, Stéphanie Le , Loughland, Carmel M. , Martinot, Jean‐Luc , McMahon, Katie L. , Meyer‐Lindenberg, Andreas , Michie, Patricia T. , Morey, Rajendra A. , Mowry, Bryan , Nyberg, Lars , Oosterlaan, Jaap , Pantelis, Christos , Pausová, Zdenka , Penninx, Brenda W.J.H. , Polderman, Tinca J. C. , Posthuma, Daniëlle , Rowland, Laura M. , Sachdev, Perminder S. , Sämann, Philipp G. , Schall, Ulrich , Schumann, Günter , Scott, Rodney J. , Sim, Kang , Smoller, Jordan W., Sommer, Iris E. , Pourcain, Beaté St , Stein, Dan J. , Ent, Dennis van ‘t , Völzke, Henry , Weber, Bernd , Weinberger, Daniel R. , Wright, Margaret J. , Zhou, Juan , Thompson, Paul M. , Medland, Sarah E. , Seppi, Klaus , Duijn, Cornelia M. van , Jicha, Gregory A. , Vernooij, Meike W. , Mishra, Aniket , Saba, Yasaman , Shenkman, Elizabeth , Ghanbari, Mohsen , Knol, Maria J. , Witte, A. Veronica , Kremen, Sarah , DeCarli, Charles , McMahon, Mary Agnes B , Zsembik, Leo C P , Agartz, Ingrid , Almeida, Marcio A A , Amlien, Inge K , Andersson, Micael , Ard, Tyler , Armstrong, Nicola J , Atkins, Joshua R , Bernard, Manon , Brouwer, Rachel M , Buimer, Elizabeth E L , Chen, Qiang , Cheung, Joshua W , Couvy-Duchesne, Baptiste , Dale, Anders M , de Araujo, Tânia K , de Zubicaray, Greig I , Dohm, Katharina , Ehrlich, Stefan , Engelbrecht, Hannah-Ruth , Fedko, Iryna O , Ford, Judith M , Fukunaga, Masaki , Garrett, Melanie E , Green, Melissa J , Grotegerd, Dominik , Gurholt, Tiril P , Gutman, Boris A , Hansell, Narelle K , Harris, Mathew A , Harrison, Marc B , Haswell, Courtney C , Hauser, Michael , Herms, Stefan , Hoehn, David , Hoffmann, Per , Holleran, Laurena , Hoogman, Martine , Hottenga, Jouke-Jan , Ikeda, Masashi , Janowitz, Deborah , Jansen, Iris E , Jia, Tianye , Jockwitz, Christiane , Kanai, Ryota , Karama, Sherif , Kaufmann, Tobias , Kikuchi, Masataka , Klein, Marieke , Knodt, Annchen R , Krämer, Bernd , Lee, Phil H , Lewis, Lindsay B , Lopes-Cendes, Iscia , Luciano, Michelle , Macciardi, Fabio , Marquand, Andre F , Melzer, Tracy R , Mirza-Schreiber, Nazanin , Moreira, Jose C V , Mühleisen, Thomas W , Najt, Pablo , Olde Loohuis, Loes M , Orfanos, Dimitri Papadopoulos , Pearson, John F , Pitcher, Toni L , Quidé, Yann , Ragothaman, Anjanibhargavi , Reay, William R , Reinbold, Céline S , Repple, Jonathan , Richard, Geneviève , Riedel, Brandalyn C , Rocha, Cristiane S , Mota, Nina Roth , Salminen, Lauren , Saremi, Arvin , Saykin, Andrew J , Schlag, Fenja , Schofield, Peter R , Secolin, Rodrigo , Shapland, Chin Yang , Shen, Li , Shin, Jean , Shumskaya, Elena , Sprooten, Emma , Thalamuthu, Anbupalam , Turner, Jessica A , Vallerga, Costanza Ludovica , van Eijk, Liza , van Erp, Theo G M , van Haren, Neeltje E M , van Rooij, Daan , van Tol, Marie-José , Veldink, Jan H , Verhoef, Ellen , Walton, Esther , Wang, Mingyuan , Wang, Yunpeng , Wardlaw, Joanna Marguerite , Wen, Wei , Westlye, Lars T , Witt, Stephanie H , Wittfeld, Katharina , Wolf, Christiane , Wolfers, Thomas , Wu, Jing Qin , Yasuda, Clarissa L , Zhang, Zuo , Artiges, Eric , Ayesa-Arriola, Rosa , Belger, Aysenil , Cichon, Sven , Curran, Joanne E , Dennis, Michelle F , Djurovic, Srdjan , Doherty, Colin P , Garijo, Daniel , Gowland, Penny A , Green, Robert C. , Häusler, Alexander N , Ho, Beng-Choon , Hoffmann, Wolfgang U , Holsboer, Florian , Homuth, Georg , Hosten, Norbert , Jack, Clifford R , Jang, MiHyun , Jansen, Andreas , Krug, Axel , Lim, Kelvin O , Luykx, Jurjen J , Mathalon, Daniel H , Mattay, Venkata S , McEwen, Sarah C , Melle, Ingrid , Morris, Derek W , Mueller, Bryon A. , Nordvik, Jan E , Nöthen, Markus M , O'Leary, Daniel S , Preda, Adrian , Rasser, Paul E , Ratnakar, Varun , Steen, Vidar M , Torres, Fábio R , Veltman, Dick J , Voyvodic, James T , Whelan, Robert , Yamamori, Hidenaga , Adams, Hieab H H , López, Oscar L. , Mazoyer, Bernard , Mosley, Thomas H. , Satizabal, Claudia L , Seshadri, Sudha , Alvim, Marina K M , Anderson, Tim J , Andreassen, Ole A , Bastin, Mark E , Beckham, Jean C , Boomsma, Dorret I , Brodaty, Henry , Buitelaar, Jan K , Bustillo, Juan R , Cahn, Wiepke , Cairns, Murray J , Calhoun, Vince D. , Carr, Vaughan J , Cavalleri, Gianpiero L , Corvin, Aiden , Crespo-Facorro, Benedicto , Dalrymple-Alford, John C , Dannlowski, Udo , de Geus, Eco J C , Depondt, Chantal , Desrivières, Sylvane , Donohoe, Gary , Espeseth, Thomas , Fisher, Simon E , Flor, Herta , Francks, Clyde , Franke, Barbara , Gollub, Randy L , Håberg, Asta K , Hartman, Catharina A , Henskens, Frans A , Hillegers, Manon H J , Hoekstra, Pieter J , Holmes, Avram J , Hulshoff Pol, Hilleke E , Jönsson, Erik G , Kennedy, Martin A , Kircher, Tilo T J , Kwok, John B J , Le Hellard, Stephanie , Martin, Nicholas G , McMahon, Katie L , Meyer-Lindenberg, Andreas , Michie, Patricia T , Morey, Rajendra A , Mowry, Bryan , Oosterlaan, Jaap , Ophoff, Roel A , Pantelis, Christos , Pausova, Zdenka , Penninx, Brenda W J H , Polderman, Tinca J C , Posthuma, Danielle , Rietschel, Marcella , Roffman, Joshua L , Sachdev, Perminder S , Schall, Ulrich , Sim, Kang , Sommer, Iris E , St Pourcain, Beate , Stein, Dan J , Toga, Arthur W , Trollor, Julian N , Van der Wee, Nic J A , van 't Ent, Dennis , Walter, Henrik , Weber, Bernd , Weinberger, Daniel R , Wright, Margaret J , Zhou, Juan , Stein, Jason L , Thompson, Paul M , Medland, Sarah E , de Zwarte, Sonja M C , Ching, Christopher R K , Thomopoulos, Sophia I , Cendes, Fernando , Teumer, Alexander , van Duijn, Cornelia M , Debette, Stephanie , Seppi, Klaus , Hashimoto, Ryota , Jicha, Gregory A , Ge, Tian , Kremen, Sarah , Agartz, Ingrid , Alnæs, Dag , Ashley‐Koch, Allison E. , Bülow, Robin , Bürger, Christian, Chakravarty, M. Mallar , Dohm, Katharina , Lam, Max , Lett, Tristram A. P. , Lopes‐Cendes, Íscia , Nho, Kwangsik T. , Pütz, Benno , Rashid, Faisal M. , Saykin, Andrew J. , Schofield, Peter R. , Shen, Li , Veldink, Jan H. , Witt, Stephanie H. , Gil, Yolanda , Jack, Clifford R. , Kimbrel, Nathan A. , Kolskår, Knut K. , Matthews, Sarah , Nauck, Matthias A. , Opel, Nils , Pike, G. Bruce , Launer, Lenore J. , Mosley, Thomas H. , Seshadri, Sudha , Yang, Qiong , Initiative¶, Alzheimer’s Disease Neuroimaging, Initiative¶, Parkinson’s Progression Markers, Andreassen, Ole A. , Vásquez, Alejandro Arias , Bastin, Mark E. , Baune, Bernhard , Fernández, Guillén , Grabe, Hans Jörgen , Hopkins, William Donald , Jernigan, Terry L. , Kochunov, Peter V , Kwok, John B. , Martin, Nicholas G. , McDonald, Colm , Ophoff, Roel A. , Paus, Tomáš , Sisodiya, Sanjay , Smoller, Jordan W. , Toga, Arthur W. , Walter, Henrik , Stein, Jason L.

Mayo Clinic

Science | March 19, 2020 | Volume: 367 | Issue: 6484 | Pages: No page available

10.1126/science.aay6690 | PMID 32193296 Get It

INTRODUCTION The cerebral cortex underlies our complex cognitive capabilities. Variations in human cortical surface area and thickness are associated with neurological, psychological, and behavioral traits and can be measured in vivo by magnetic resonance imaging (MRI). Studies in model organisms have identified genes that influence cortical structure, but little is known about common genetic variants that affect human cortical structure. RATIONALE To identify genetic variants associated with human cortical structure at both global and regional levels, we conducted a genome-wide association meta-analysis of brain MRI data from 51,665 individuals across 60 cohorts. We analyzed the surface area and average thickness of the whole cortex and 34 cortical regions with known functional specializations. RESULTS We identified 369 nominally genome-wide significant loci ( P < 5 × 10 −8 ) associated with cortical structure in a discovery sample of 33,992 participants of European ancestry. Of the 360 loci for which replication data were available, 241 loci influencing surface area and 66 influencing thickness remained significant after replication, with 237 loci passing multiple testing correction ( P < 8.3 × 10 −10 ; 187 influencing surface area and 50 influencing thickness). Common genetic variants explained 34% (SE = 3%) of the variation in total surface area and 26% (SE = 2%) in average thickness; surface area and thickness showed a negative genetic correlation ( r G = −0.32, SE = 0.05, P = 6.5 × 10 −12 ), which suggests that genetic influences have opposing effects on surface area and thickness. Bioinformatic analyses showed that total surface area is influenced by genetic variants that alter gene regulatory activity in neural progenitor cells during fetal development. By contrast, average thickness is influenced by active regulatory elements in adult brain samples, which may reflect processes that occur after mid-fetal development, such as myelination, branching, or pruning. When considered together, these results support the radial unit hypothesis that different developmental mechanisms promote surface area expansion and increases in thickness. To identify specific genetic influences on individual cortical regions, we controlled for global measures (total surface area or average thickness) in the regional analyses. After multiple testing correction, we identified 175 loci that influence regional surface area and 46 that influence regional thickness. Loci that affect regional surface area cluster near genes involved in the Wnt signaling pathway, which is known to influence areal identity. We observed significant positive genetic correlations and evidence of bidirectional causation of total surface area with both general cognitive functioning and educational attainment. We found additional positive genetic correlations between total surface area and Parkinson’s disease but did not find evidence of causation. Negative genetic correlations were evident between total surface area and insomnia, attention deficit hyperactivity disorder, depressive symptoms, major depressive disorder, and neuroticism. CONCLUSION This large-scale collaborative work enhances our understanding of the genetic architecture of the human cerebral cortex and its regional patterning. The highly polygenic architecture of the cortex suggests that distinct genes are involved in the development of specific cortical areas. Moreover, we find evidence that brain structure is a key phenotype along the causal pathway that leads from genetic variation to differences in general cognitive function. Identifying genetic influences on human cortical structure. ( A ) Measurement of cortical surface area and thickness from MRI. ( B ) Genomic locations of common genetic variants that influence global and regional cortical structure. ( C ) Our results support the radial unit hypothesis that the expansion of cortical surface area is driven by proliferating neural progenitor cells. ( D ) Cortical surface area shows genetic correlation with psychiatric and cognitive traits. Error bars indicate SE. IMAGE CREDITS: (A) K. COURTNEY; (C) M. R. GLASS
Phase 1/2 trial of acalabrutinib plus pembrolizumab (Pem) in relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL).
Maddocks, Kami J. , Vos, Sven de , Lyons, Roger M. , Edenfield, William J. , Sharman, Jeff P. , Yimer, Habte, Chan, Edward M. , Patel, Priti, Simone, Christopher Di, Gandhi, Mitul, Vaughn, Jennifer , Cheson, Bruce D. , Samaniego, Felipe , Witzig, Thomas E. , Vose, Julie M. , Wei, Helen , Kolibaba, Kathryn S.

Mayo Clinic

Journal of Clinical Oncology | March 12, 2020 | Volume: 37 | Issue: 15_suppl | Pages: 7519-7519

10.1200/jco.2019.37.15_suppl.7519 Get It

7519 Background: Acalabrutinib, a highly selective, potent, covalent Bruton tyrosine kinase (BTK) inhibitor, has a 24% overall response rate (ORR) as a single agent in R/R DLBCL. Pem targets PD-1, an immune checkpoint that limits anticancer responses. Pem showed responses in patients (pts) with Richter transformation who failed ibrutinib and can augment acalabrutinib activity in vitro. This study assessed acalabrutinib + Pem in R/R DLBCL. Methods: Pts with DLBCL, ≥1 prior chemoimmunotherapy and no prior allogeneic transplant received acalabrutinib 100 mg PO BID until progressive disease (PD) + Pem 200 mg/kg IV Q3W up to 2 y. Germinal center B-cell (GCB) vs non-GCB subtype was assessed by immunohistochemistry. Primary endpoint was safety. Results: Sixty-one pts (30 GCB; 31 non-GCB) were accrued, with a median age (range) of 67 y (30-85) and a median of 3 (1-8) prior therapies; 1 pt had prior autologous transplant. The most common Gr 3/4 adverse events (AEs) were neutropenia (15%) and anemia (11%). Gr 5 AEs were respiratory failure (n=3), sepsis, septic shock and abdominal abscess (n=1 each). All Gr atrial fibrillation was 5% (n=3), and major hemorrhage (≥ Gr 3) was 11% (4 gastrointestinal, 1 pulmonary, 1 epistaxis, 1 hematuria). Gr 3/4 immune-mediated events were elevated alanine aminotransferase (n=4), pneumonitis (n=2) and colitis (n=1). The ORR was 26% (Table) and was similar in GCB (27%) and non-GCB (26%) tumors. The median time on study was 5.2 mo (0.4-30.4+). Acalabrutinib/Pem discontinuations were due to PD (62%/56%) and AEs (15%/26%). As of June 2018, 10 pts remain on study; 6 on active therapy and 7 without PD. Conclusions: Acalabrutinib + Pem was well tolerated, with meaningful activity and some exceptional responders (>24 mo) in these R/R DLBCL pts. Randomized trials of the combination vs single agent are needed. Clinical trial information: NCT02362035. [Table: see text]
A randomized controlled trial of a novel artificial intelligence-based smartphone application to optimize the management of cancer-related pain.
Kamdar, Mihir , Agboola, Stephen , Fischer, Nils , Rinaldi, Simone , Strand, Jacob J. , Traeger, Lara , El‐Jawahri, Areej , Jackson, Vicki A. , Jethwani, Kamal , Centi, Amanda Jayne , Temel, Jennifer S. , Greer, Joseph Andrew , Kvedar, Joseph C.

Mayo Clinic

Journal of Clinical Oncology | March 12, 2020 | Volume: 37 | Issue: 15_suppl | Pages: 11514-11514

10.1200/jco.2019.37.15_suppl.11514 Get It

11514 Background: Cancer pain is a significant problem that impairs patient quality of life and increases healthcare utilization. ePAL is a smartphone application that utilizes patient-reported outcomes (PROs) and artificial intelligence (AI) to optimize cancer pain management. This randomized controlled trial examined the impact of ePAL on cancer pain severity, attitudes toward cancer pain, and healthcare utilization. Methods: Patients with pain from metastatic solid tumors (n = 112) undergoing treatment in a palliative care clinic were randomized to either a control group (n = 56) that received usual care or an intervention group (n = 56) that received ePAL in addition to usual care for 8 weeks. Measures of pain severity (Brief Pain Inventory), attitudes towards cancer treatment (Barriers Questionnaire II) and anxiety (General Anxiety Disorder-7) were assessed. We used repeated measures mixed modeling to assess change in outcome measures over time. We also conducted a chart review to identify pain-related hospital admissions and emergency department (ED) visits and compared risk between study groups. Results: Pain severity (BPI) and negative attitudes toward cancer treatment (BQ-II) decreased significantly for those assigned to ePAL compared to controls (ß = -0.09, p = 0.034 and ß = -0.037, p = 0.042, respectively). Patients assigned to ePAL reported higher anxiety scores compared to controls (ß = 0.21, p = 0.015). Patients assigned to ePAL had significantly fewer pain-related hospital admissions (n = 4 vs. n = 20, per patient risk ratio 0.31, p = 0.018) and fewer pain-related admissions through the ED (n = 2 vs. n = 14, per patient risk ratio 0.18, p = 0.008) compared to control group. Conclusions: To our knowledge, this is the first mobile app to utilize patient reported outcomes and artificial intelligence to significantly decrease pain scores and pain-related hospitalizations in patients with cancer-related pain. Future directions include examining the efficacy of ePAL in settings with limited access to palliative care.
Risk of cancer treatment-related osteoporosis and fractures among women with breast cancer receiving aromatase inhibitors
Mincey, Betty A., Duh, Mei Sheng , Thomas, Simu K. , Moyneur, Érick, Marynchencko, Maryna, Boyce, Simone Peart, Pérez, E.

Mayo Clinic

Journal of Clinical Oncology | March 9, 2020 | Volume: 24 | Issue: 18_suppl | Pages: 557-557

10.1200/jco.2006.24.18_suppl.557 Get It

557 Background: Aromatase inhibitors (AIs) are a novel hormonal therapy for breast cancer. However, AIs can cause bone loss by blocking estrogen production. This study aims to assess the association between AIs and treatment-related bone loss in a large managed care population of women with breast cancer. Methods: Using medical and pharmacy claims data from over 5 million beneficiaries between 01/01/1998 and 01/31/2005, we identified 12,368 patients with ≥ 2 breast cancer claims in a 6-month period, who also had no bone metastasis and no prior osteoporosis or fracture claims. Patients who received anti-estrogen therapy were also excluded to remove the protective confounding effects. 1,354 patients receiving an AI (anastrozole, exemestane, letrozole) were compared to 11,014 controls who did not receive an AI with respect to their risk of bone loss. The observation start date for the AI and control groups was defined as the service date of the first AI claim and breast cancer claim, respectively. The bone loss endpoints analyzed were osteoporosis (including osteopenia) and clinical fractures. Results: The univariate analysis found that the prevalence of osteoporosis was 8.7% in the AI group vs. 7.1% in the control group, resulting in a statistically significant relative risk of 1.3 (95% CI=1.1–1.6, p=0.01). The prevalence of bone fracture was also statistically significantly elevated in the AI group compared to the controls (13.5% vs. 10.3%) with a relative risk of 1.4 (95% CI=1.2–1.6, p=0.001). Multivariate Cox proportional hazards regressions showed that after adjusting for age and comorbidities, the risk of bone loss remained statistically significantly higher in the AI group than the non-AI group, with 27% (95% CI=4%-55%, p=0.02) and 21% (95% CI=3%-43%, p=0.02) increase in the risk of osteoporosis and fractures, respectively. Conclusions: This retrospective longitudinal analysis of a large cohort of breast cancer patients corroborates previous findings from smaller clinical trials and demonstrates that AI therapies carry an increased risk of bone loss. Monitoring and treatment management strategies to alleviate bone loss risk are warranted in women receiving AI for breast cancer. [Table: see text]
Ki-67 Labeling Index in Pulmonary Carcinoid Tumors: Comparison Between Small Biopsy and Resection Using Tumor Tracing and Hot Spot Methods
Kroneman, Trynda, Jenkins, Sarah M. , Terra, Simone , Molina, Julian R. , Mounajjed, Taofic, Roden, Anja C. , Boland, Jennifer M. , Kroneman, Trynda N, Terra, Simone B S P, Molina, Julian, Xie, Hao

Mayo Clinic

Archives of Pathology & Laboratory Medicine | January 16, 2020 | Volume: 144 | Issue: 8 | Pages: 982-990

10.5858/arpa.2019-0374-oa | PMID 31944862 Get It

Context.— Pulmonary carcinoids are classified as typical or atypical by assessing necrosis and mitoses, which usually cannot be adequately assessed on small biopsies. Ki-67 is not currently used to grade pulmonary carcinoids, but it may be helpful to determine preliminary grade in biopsies. However, the rate at which Ki-67 could underestimate or overestimate grade on small biopsies has not been well studied. Objective.— To compare Ki-67 labeling obtained on small biopsies to subsequent resection. Design.— Ki-67 was performed on paired biopsy and resection specimens from 55 patients. Slides were scanned using Aperio ScanScope. Labeling index was determined using automated hot spot and tumor tracing methods. Results.— The study included 41 typical and 14 atypical carcinoids. Atypical carcinoids were larger and had more distant metastases. Death from disease occurred in 3 patients (all had atypical carcinoids). Median hot spot Ki-67 labeling index was greater in resection compared with biopsy by 0.7% (P = .02). Median tumor tracing Ki-67 was lower in resection compared with biopsy by 0.5% (P &lt; .001). Receiver-operating characteristic analysis showed similar hot spot Ki-67 cutoffs to predict atypical histology (3.5% for biopsy, 3.6% for resection; area under the curve [AUC], 0.75 and 0.74, respectively). Different optimal cutoffs were needed for tracing method based on biopsy (2.1%; AUC, 0.75) compared with resection (1.0%; AUC, 0.67). Conclusions.— Hot spot Ki-67 tends to underestimate grade on small biopsies, whereas grade is overestimated by tumor tracing. Hot spot Ki-67 cutoff of 3.5% predicted atypical histology for both biopsy and resection. Different biopsy and resection cutoffs were necessary for tumor tracing, which would make clinical implementation more difficult.
Expanding the CRISPR Toolbox with ErCas12a in Zebrafish and Human Cells
Wierson, Wesley A. , Simone, Brandon W. , WareJoncas, Zachary , Mann, Carla M. , Welker, Jordan M. , Kar, Bibekananda , Emch, Michael J. , Gendron, William A.C. , Kar, Bibekananda , Friedberg, Iddo , Barry, Michael A. , Clark, Karl J. , Dobbs, Drena L , McGrail, Maura , Ekker, Stephen C. , Essner, Jeffrey J.

Mayo Clinic

The CRISPR Journal | December 20, 2019 | Volume: 2 | Issue: 6 | Pages: 417-433

10.1089/crispr.2019.0026 | PMID 31742435 Get It

CRISPR and CRISPR-Cas effector proteins enable the targeting of DNA double-strand breaks to defined loci based on a variable length RNA guide specific to each effector. The guide RNAs are generally similar in size and form, consisting of a ∼20 nucleotide sequence complementary to the DNA target and an RNA secondary structure recognized by the effector. However, the effector proteins vary in protospacer adjacent motif requirements, nuclease activities, and DNA binding kinetics. Recently, ErCas12a, a new member of the Cas12a family, was identified in Eubacterium rectale . Here, we report the first characterization of ErCas12a activity in zebrafish and expand on previously reported activity in human cells. Using a fluorescent reporter system, we show that CRISPR-ErCas12a elicits strand annealing mediated DNA repair more efficiently than CRISPR-Cas9. Further, using our previously reported gene targeting method that utilizes short homology, GeneWeld, we demonstrate the use of CRISPR-ErCas12a to integrate reporter alleles into the genomes of both zebrafish and human cells. Together, this work provides methods for deploying an additional CRISPR-Cas system, thus increasing the flexibility researchers have in applying genome engineering technologies.
ClinGen Myeloid Malignancy Variant Curation Expert Panel recommendations for germline RUNX1 variants
Luo, Xi , Feurstein, Simone , Mohan, Shruthi , Jackson, Sarah A. , Keel, Sioḃán , Chicka, Michael C., Brown, Anna , Agarwal, Anupriya , Luo, Minjie , Li, Zejuan , Ross, Justyne , Pineda‐Alvarez, Daniel , Bertuch, Alison A. , Mehta, Nikita , Vulliamy, Tom, Wang, Ying , Nichols, Kim E. , Malcovati, Luca , Walsh, Michael F. , Rawlings, Lesley , Soulier, Jean , Raimbault, Anna , Zhang, Liying , Ryan, Gabriella, Speck, Nancy A. , Wu, David , Godley, Lucy A. , Malcovati, Luca , Godley, Lucy A , Brown, Anna L , Jackson, Sarah A , Nichols, Kim E , Porter, Christopher C. , Kesserwan, Chimene A. , Baliakas, Panagiotis , DiNardo, Courtney D. , McWeeney, Shannon K. , Routbort, Mark J. , Ryan, Gabriella, Plon, Sharon E.

Mayo Clinic

Blood Advances | October 16, 2019 | Volume: 3 | Issue: 20 | Pages: 2962-2979

10.1182/bloodadvances.2019000644 | PMID 31648317 Get It

Key Points The ClinGen MM-VCEP has specified RUNX1-specific curation rules to address gene function, gene-specific domains, and phenotypic criteria. RUNX1-specific criteria resulted in a reduction in CONF and VUS variants by 33%, emphasizing the need for expert variant curation.